Program
Scientific Program
- May 14 (Thu)
- 09:00-11:30
- Year in Review
- Room 1 (3F)
- KOR
09:00-09:30
Emerging Treatments in Rheumatoid Arthritis
09:30-10:00
Psoriatic Arthritis
10:00-10:30
Recent Advances in Lupus Nephritis: A Year in Review
10:30-11:00
Sjögren's Disease
11:00-11:30
ANCA-Associated Vasculitis
- May 14 (Thu)
- 12:00-13:00
- Luncheon Symposium 1 [Celltrion]
- Efficacy of Infliximab SC in Treatment of axSpA
- Room 1 (3F)
- KOR
12:00-13:00
From Clinical Trials to Real-World Evidence: The Totality of Evidence for Subcutaneous Infliximab
- May 14 (Thu)
- 13:00-14:30
- Presidential Plenary Session
- Room 1 (3F)
- KOR
13:00-13:40
A Life So Good, Unique
13:40-14:20
Charting a Path to Research Excellence in Rheumatology
- May 14 (Thu)
- 15:30-17:00
- International Joint Symposium (KCR and APLAR member)
- Room 1 (3F)
- ENG
- Chairs
- Kichul Shin (Seoul Nat'l Univ., Korea)
- Lai-Shan Tam (The Chinese Univ. of Hong Kong, Hong Kong)
15:30-15:50
Prevention of Bone Damage in Psoriatic Arthritis
15:50-16:10
Driving Quality Care in RA in the APLAR Region: Leveraging Registry Data from Patients and Clinicians
16:10-16:30
State-of-the-Art Systemic Lupus Erythematosus
16:30-16:50
Social Justice and Rheumatology
- May 14 (Thu)
- 17:00-18:00
- Evening Symposium 1 [Novartis]
- Unlocking Sjögren’s Disease: Key Findings from the NEPTUNUS Study
- Room 1 (3F)
- ENG
17:00-18:00
Unlocking Sjögren’s Disease: Key Findings from the NEPTUNUS Study
- May 14 (Thu)
- 12:00-13:00
- Luncheon Symposium 2 [Samsung Bioepis]
- Spondyloarthritis
- Room 2 (3F)
- ENG
12:00-13:00
The Evolving Landscape of axSpA Treatment: Real-World Insights from the European Experience
- May 14 (Thu)
- 13:00-14:30
- Free Paper Session
- Room 2 (3F)
- ENG
- May 14 (Thu)
- 15:30-17:00
- Free Paper Session
- Room 2 (3F)
- ENG
- May 14 (Thu)
- 17:00-18:00
- Evening Symposium 2 [Johnson&Johnson]
- SIMPONI SC Efficacy in AS
- Room 2 (3F)
- ENG
17:00-18:00
Optimizing SIMPONI’s Persistence through Low Immunogenicity with Effective EMM Control
- May 14 (Thu)
- 12:00-13:00
- Luncheon Symposium 3 [GSK]
- Shingles Prevention as a Priority in Rheumatology
- Room 3 (5F)
- ENG
12:00-13:00
Timings and Targets in Vaccine-Preventable Diseases: Shingles Prevention in Rheumatology
- May 14 (Thu)
- 13:00-14:30
- Free Paper Session
- Room 3 (5F)
- ENG
- May 14 (Thu)
- 15:30-17:00
- Free Paper Session
- Room 3 (5F)
- ENG
- May 14 (Thu)
- 14:30-15:30
- Poster Viewing & Tour 1
- Poster Zone (5F)
- ENG
- May 15 (Fri)
- 08:00-09:00
- Breakfast Symposium 1 [Samsung Bioepis]
- Osteoporosis
- Room 1 (3F)
- KOR
08:00-09:00
Optimizing Fracture Prevention in Rheumatic Patients: Updates on High-Risk Management Strategies
- May 15 (Fri)
- 09:00-10:00
- Keynote Lecture 1
- Room 1 (3F)
- ENG
09:00-10:00
Central Role for EBV in Systemic Lupus Erythematosus
- May 15 (Fri)
- 10:30-12:00
- International Symposium 1_Mastering the Spondyloarthritis Spectrum
- Room 1 (3F)
- ENG
10:30-11:00
Past, Present, and New Horizons in Spondyloarthritis Research
11:00-11:30
Long-Term Prognosis and Outcomes from Cohort Data
11:30-12:00
Clinical Trial and Real-World Data for Optimal Treatment Decisions
- May 15 (Fri)
- 12:00-13:00
- Luncheon Symposium 4 [Abbvie]
- Exploring Disease Control Strategies of JAK inhibitor for Rheumatoid Arthritis
- Room 1 (3F)
- KOR
12:00-13:00
Optimizing Treatment for Early Remission in Rheumatoid Arthritis with Upadacitinib
- May 15 (Fri)
- 13:00-14:30
- International Symposium 2_KCR-GOUT/G-CAN Joint Symposium
- Room 1 (3F)
- ENG
13:00-13:30
Gout 2026: New Biology, New Therapies
13:30-14:00
Emerging Urate-Lowering Drugs and Their Application to Gout Treatment Strategies
14:00-14:30
Beyond Crystal Deposition: Gouty Tophi as Structured Inflammatory Microenvironments
- May 15 (Fri)
- 15:30-17:00
- International Symposium 3_Contemporary Understanding and Innovative Treatments for Fibromyalgia
- Room 1 (3F)
- ENG
15:30-16:00
Distinguishing Inflammatory and Nociplastic Pain: Clinical Implications for Fibromyalgia and Inflammatory Arthritis
16:00-16:30
EULAR Perspectives on Fibromyalgia: From Pathophysiology to Updated Management Recommendations
16:30-17:00
Is Fibromyalgia an Autoimmune Disease? Rethinking the Evidence
- May 15 (Fri)
- 08:00-09:00
- Breakfast Symposium 2 [Pfizer & Hanlim MS]
- The Role of Xeljanz
- Room 2 (3F)
- KOR
08:00-09:00
As First Approved JAK, Broaden Indications, and Over 10-Year Experience in Korea
- May 15 (Fri)
- 10:30-12:00
- Free Paper Session
- Room 2 (3F)
- ENG
- May 15 (Fri)
- 12:00-13:00
- Luncheon Symposium 5 [Eisai Korea Inc.]
- The Difference among JAK-Inhibitors
- Room 2 (3F)
- ENG
12:00-13:00
Balancing Efficacy and Safety: Real-World Experience and Clinical Benefits of Filgotinib
- May 15 (Fri)
- 13:00-14:30
- Free Paper Session
- Room 2 (3F)
- ENG
- May 15 (Fri)
- 15:30-17:00
- Free Paper Session
- Room 2 (3F)
- ENG
- May 15 (Fri)
- 08:00-09:00
- Breakfast Symposium 3 [Celltrion]
- Tocilizumab Biosimilar for Rheumatoid Arthritis
- Room 3 (5F)
- KOR
08:00-09:00
Demonstrating Efficacy and Safety Equivalence of Avtozma: Results from Phase III Clinical Trial
- May 15 (Fri)
- 10:30-12:00
- KCR-KSBMR Joint Symposium_Clinical Osteoimmunology in Practice
- Room 3 (5F)
- ENG
- Chairs
- Seung Cheol Shim (Chungnam Nat'l Univ., Korea)
- Je-Yong Choi (Kyungpook Nat'l Univ., Korea)
10:30-11:00
Immune Cells and Bone Interaction
11:00-11:30
Cellular Crosstalk in Bone: A Therapeutic Perspective
11:30-12:00
Restoration of BMD by Treatment of Rheumatic Diseases
- May 15 (Fri)
- 12:00-13:00
- Luncheon Symposium 6 [Novartis]
- Bending the AS Curve Early with IL-17A Inhibition
- Room 3 (5F)
- KOR
12:00-13:00
From Early Control to Sustained Outcomes with Secukinumab in AS
- May 15 (Fri)
- 13:00-14:30
- KCR-KCPCI Joint Symposium
- Room 3 (5F)
- ENG
13:00-13:30
Transition Care in Japan
13:30-14:00
Caring for Childhood-Onset SLE in Adult Rheumatology Care
14:00-14:30
Still's Disease across the Age Spectrum: Integrating Recent EULAR/PReS Recommendations
- May 15 (Fri)
- 15:30-17:00
- Health Insurance Committee Session
- Room 3 (5F)
- KOR
- May 15 (Fri)
- 14:30-15:30
- Poster Viewing & Tour 2
- Poster Zone (5F)
- ENG
- May 16 (Sat)
- 08:00-09:00
- Breakfast Symposium 4 [Eisai Korea Inc.]
- Personalized Treatment for RA
- Room 1 (3F)
- KOR
08:00-09:00
Identifying Right Patients for JAKi Therapy in RA
- May 16 (Sat)
- 09:00-10:00
- Keynote Lecture 2
- Room 1 (3F)
- ENG
09:00-10:00
Immune Checkpoint Receptors in Autoimmune Diseases
- May 16 (Sat)
- 10:30-12:00
- International Symposium 4 (KCR-JCR Research Committee)_Translating Genetic Epidemiology into Clinical Rheumatology
- Room 1 (3F)
- ENG
10:30-11:00
Mapping Genetic Architecture of Autoimmune Rheumatic Diseases: From GWAS Discoveries to Mechanistic Insights
11:00-11:30
Genetic Epidemiology in Clinical Rheumatology: Cohort-Based Insights from Korea
11:30-11:50
Panel Discussion_Future Collaboration between KCR and JCR in the Field of Clinical Research
Yoshiya Tanaka (Univ. of Occupational and Environmental Health, Japan)
Sang-Cheol Bae (Hanyang Univ., Korea)
11:50-12:00
KCR–JCR Clinical Research Committee MOU Signing Ceremony
- May 16 (Sat)
- 12:00-13:00
- Luncheon Symposium 7 [Johnson&Johnson]
- SIMPONI IV Efficacy in RA
- Room 1 (3F)
- KOR
12:00-13:00
Rapid Onset Impact of Biologic from the Start: Golimumab IV in RA Treatment
- May 16 (Sat)
- 13:00-15:00
- Medical Humanities Session
- Room 1 (3F)
- KOR
13:00-14:00
The Physician-Patient Relationship in the Age of Medical Artificial Intelligence
14:00-15:00
Physicians' Social Media Use and Social Trust
- May 16 (Sat)
- 08:00-09:00
- Breakfast Symposium 5 [Daewoong]
- The Expanding Therapeutic Spectrum in Rheumatic Diseases
- Room 2 (3F)
- KOR
08:00-09:00
Optimizing Treatment Strategies with Biosimilars and JAK Inhibitors in Rheumatology Practice
- May 16 (Sat)
- 10:30-12:00
- Free Paper Session
- Room 2 (3F)
- ENG
- May 16 (Sat)
- 12:00-13:00
- Luncheon Symposium 8 [Amgen & ChongKunDang]
- Optimizing Osteoporosis Care for Rheumatology Patients
- Room 2 (3F)
- KOR
12:00-13:00
Why Prolia? Facts About Biologics and Biosimilars
- May 16 (Sat)
- 13:30-15:00
- Free Paper Session
- Room 2 (3F)
- ENG
- May 16 (Sat)
- 08:00-09:00
- Breakfast Symposium 6 [Abbvie]
- Exploring Disease Control Strategies of JAK inhibitor for Axial Spondyloarthritis
- Room 3 (5F)
- KOR
08:00-09:00
Optimizing Treatment Across Diverse Patient Profiles in Axial Spondyloarthritis with Upadacitinib
- May 16 (Sat)
- 10:30-12:00
- Free Paper Session
- Room 3 (5F)
- ENG
- May 16 (Sat)
- 12:00-13:00
- Luncheon Symposium 9 [JW Pharmaceutical]
- Targeted Therapies in Systemic Vasculitis
- Room 3 (5F)
- KOR
12:00-13:00
The Role of IL-6 Pathway Blockade: Clinical Outcome of Tocilizumab Therapy in GCA
- May 16 (Sat)
- 13:30-15:00
- Free Paper Session
- Room 3 (5F)
- ENG
- May 16 (Sat)
- 10:00-10:30
- Poster Viewing & Tour 3
- Poster Zone (5F)
- ENG
- May 16 (Sat)
- 13:00-13:30
- Poster Viewing
- Poster Zone (5F)
